ArticleBioengineering (Basel, Switzerland)2025
Deep Learning for Predicting Spheroid Viability: Novel Convolutional Neural Network Model for Automating Quality Control for Three-Dimensional Bioprinting.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- From Technological Innovation to Clinical Translation: Progress and Challenges in 3D Bioprinting for the Development of Breast Cancer Bone Metastasis Models.Advanced healthcare materials · 2026Review
- Depth-Dependent Performance of Residual Networks for Low-Count PET Image Restoration Using a Dedicated 3D-Printed Striatum Phantom.Bioengineering (Basel, Switzerland) · 2026Article
- Prospective Assessment of Embryoid Body by Deep Learning on Label-Free Time-Lapse Images from the Microwell Array.Biomedicines · 2026Article
- Non-invasive quantification of viability in liver spheroids using deep learning.Frontiers in bioengineering and biotechnology · 2026Article
- Machine learning-supported identification of necrosis in colorectal and pancreatic cancer spheroids.PloS one · 2026Article
- 3D Bioprinting and Artificial Intelligence for Tumor Microenvironment Modeling: A Scoping Review of Models, Methods, and Integration Pathways.Molecular pharmaceutics · 2025Article
- More than just life and death: advances in imaging and analysis for 3D-bioprinted tissues.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spheroids serve as the building blocks for three-dimensional (3D) bioprinted tissue patches. When larger than 500 μm, the desired size for 3D bioprinting, they tend to have a hypoxic core with necrotic cells. Therefore, it is critical to assess the viability of spheroids in order to ensure the successful fabrication of high-viability patches. However, current viability assays are time-consuming, labor-intensive, require specialized training, or are subject to human bias. In this study, we build a convolutional neural network (CNN) model to efficiently and accurately predict spheroid viability, using a phase-contrast image of a spheroid as its input. A comprehensive dataset of mouse mesenchymal stem cell (mMSC) spheroids of varying sizes with corresponding viability percentages, which was obtained through CCK-8 assays, was established and used to train and validate the model. The model was trained to automatically classify spheroids into one of four distinct categories based on their predicted viability: 0-20%, 20-40%, 40-70%, and 70-100%. The model achieved an average accuracy of 92%, with a consistent loss below 0.2. This deep-learning model offers a non-invasive, efficient, and accurate method to streamline the assessment of spheroid quality, thereby accelerating the development of bioengineered cardiac tissue patches for cardiovascular disease therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.